Evaluation of sulfur isotopic enrichment of urine metabolites for the differentiation of healthy and prostate cancer mice after the administration of 34S labelled yeast

Siegel, 2013, Cancer statistics, 2013, CA Cancer J. Clin., 63, 11, 10.3322/caac.21166 Ferlay, 2010, Estimates of cancer incidence and mortality in Europe in 2008, Eur. J. Cancer, 46, 765, 10.1016/j.ejca.2009.12.014 Pavlou, 2010, The cancer cell secretome: a good source for discovering biomarkers?, J. Proteomics, 73, 1896, 10.1016/j.jprot.2010.04.003 Makridakis, 2010, Secretome proteomics for discovery of cancer biomarkers, J. Proteomics, 73, 2291, 10.1016/j.jprot.2010.07.001 Bolduc, 2007, Urinary PSA: a potential useful marker when serum PSA is between 2.5ng/mL and 10ng/mL, Can. Urol. Assoc. J., 1, 377, 10.5489/cuaj.444 Takayama, 1994, Urinary prostate specific antigen levels after radical prostatectomy, J. Urol., 151, 82, 10.1016/S0022-5347(17)34877-2 DeVere White, 1992, Urinary prostate specific antigen levels: role in monitoring the response of prostate cancer to therapy, J. Urol., 147, 947, 10.1016/S0022-5347(17)37430-X Pannek, 1997, Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer, Urology, 50, 715, 10.1016/S0090-4295(97)00324-5 Schostak, 2009, Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection, J. Urol., 181, 343, 10.1016/j.juro.2008.08.119 Gamagedara, 2012, Validation study of urinary metabolites as potential biomarkers for prostate cancer detection, Bioanalysis, 4, 1175, 10.4155/bio.12.92 Jentzmik, 2010, Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors, Eur. Urol., 58, 12, 10.1016/j.eururo.2010.01.035 Rehman, 2004, Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study, Urology, 64, 1238, 10.1016/j.urology.2004.06.063 Theodorescu, 2005, Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine, Electrophoresis, 26, 2797, 10.1002/elps.200400208 Theodorescu, 2008, Discovery and validation of urinary biomarkers for prostate cancer, Proteomics Clin. Appl., 2, 556, 10.1002/prca.200780082 M’Koma, 2007, Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine, Biochem. Biophys. Res. Commun., 353, 829, 10.1016/j.bbrc.2006.12.111 Giner Martínez-Sierra, 2013, Sulphur tracer experiments in laboratory animals using 34S-labelled yeast, Anal. Bioanal. Chem., 405, 2889, 10.1007/s00216-012-6420-x Galilea San Blas, 2015, Evaluation of multi-collector inductively coupled plasma mass spectrometry (MC-ICP-MS) for sulfur metabolic studies using 34S-labelled yeast, J. Anal. Atom. Spectrom., 30, 1764, 10.1039/C4JA00383G Giner Martínez-Sierra, 2007, Biosynthesis of 34S-labelled yeast and its characterisation by multicollector-ICP-MS, J. Anal. At. Spectrom, 22, 1105, 10.1039/b706217f Gingrich, 1996, Metastatic prostate cancer in a transgenic mouse, Cancer Res., 56, 4096 Hurwitz, 2001, The TRAMP mouse as a model for prostate cancer, Curr. Protoc. Immunol., 10.1002/0471142735.im2005s45 Giner Martínez-Sierra, 2010, Evaluation of different analytical strategies for the quantification of sulfur-containing biomolecules by HPLC-ICP-MS: application to the characterisation of 34S-labelled yeast, J. Anal. At. Spectrom., 25, 989, 10.1039/b925366a